Cigarette smoking, systolic blood pressure, and cardiovascular diseases in the Asia-Pacific region by �꽌�씪
Woodward
Ueshima, Jean Woo, Dongfeng Gu, Takayoshi Ohkubo, Carlene M.M. Lawes, Il Suh and Mark 
Koshi Nakamura, Federica Barzi, Tai-Hing Lam, Rachel Huxley, Valery L. Feigin, Hirotsugu
Asia-Pacific Region
Cigarette Smoking, Systolic Blood Pressure, and Cardiovascular Diseases in the
Print ISSN: 0039-2499. Online ISSN: 1524-4628 
Copyright © 2008 American Heart Association, Inc. All rights reserved.
is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231Stroke 
doi: 10.1161/STROKEAHA.107.496752
2008;39:1694-1702; originally published online March 6, 2008;Stroke. 
 http://stroke.ahajournals.org/content/39/6/1694
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
  
 http://stroke.ahajournals.org//subscriptions/
is online at: Stroke  Information about subscribing to Subscriptions:
  
 http://www.lww.com/reprints
 Information about reprints can be found online at: Reprints:
  
document. Permissions and Rights Question and Answer process is available in the
Request Permissions in the middle column of the Web page under Services. Further information about this
Once the online version of the published article for which permission is being requested is located, click 
 can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office.Strokein
 Requests for permissions to reproduce figures, tables, or portions of articles originally publishedPermissions:
 at CONS KESLI on October 27, 2014http://stroke.ahajournals.org/Downloaded from 
Cigarette Smoking, Systolic Blood Pressure, and
Cardiovascular Diseases in the Asia-Pacific Region
Koshi Nakamura, MD; Federica Barzi, PhD; Tai-Hing Lam, MD; Rachel Huxley, DPhil;
Valery L. Feigin, MD; Hirotsugu Ueshima, MD; Jean Woo, MD; Dongfeng Gu, MD;
Takayoshi Ohkubo, MD; Carlene M.M. Lawes, PhD; Il Suh, MD; Mark Woodward, PhD;
for the Asia Pacific Cohort Studies Collaboration
Background and Purpose—Smoking and increased levels of blood pressure (BP) substantially increase the risk of
cardiovascular diseases (CVD). If these 2 risk factors have a synergistic impact on cardiovascular events, lowering BP
and quitting smoking will contribute more to reducing CVD than would be expected from ignoring their interaction.
Methods—Individual participant data were combined from 41 cohorts, involving 563 144 participants (82% Asian). During
a median of 6.8 years follow-up, 4344 coronary heart disease (CHD) and 5906 stroke events were recorded. Repeat
measures of systolic blood pressure (SBP) were used to adjust for regression dilution bias. Hazard ratios (HRs) and 95%
confidence intervals (CIs) for SBP by cigarette smoking status were estimated from Cox proportional hazard models
adjusted for age and stratified by study and sex.
Results—Data suggested a log-linear relationship between SBP and all subtypes of CVD. The HRs relating SBP to both
CHD and ischemic stroke were broadly similar irrespective of smoking status (P0.1). For hemorrhagic stroke
(intracerebral hemorrhage), the HRs (95% CIs) for an additional 10 mm Hg increment in SBP were 1.81 (1.73 to 1.90)
for present smokers and 1.66 (1.59 to 1.73) for nonsmokers (P0.003). For every subtype of cardiovascular events,
similar results were found for analyses involving only fatal events.
Conclusions—Smoking exacerbated the impact of SBP on the risk of hemorrhagic stroke. Although quitting smoking and
lowering BP are both crucial for prevention of CVD, combining the 2 could be expected to have extra beneficial effect
on preventing hemorrhagic stroke. (Stroke. 2008;39:1694-1702.)
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Nonoptimal levels of blood pressure (BP) and smokingare the first and second most common causes of death in
the world, and, together, these 2 risk factors account for more
than 20% of the global burden of premature death.1,2 In
particular, increased BP3–7 and smoking7–11 are major risk
factors for cardiovascular diseases (CVD), including coro-
nary heart disease (CHD) and stroke. Previous studies have
indicated that smoking and increased BP interact to increase
markers of cardiovascular risk, including levels of plasma
fibrinogen12 and carotid intima-media thickness.13 Hence, a
combination of raised BP and smoking may have a synergis-
tic impact on cardiovascular events, especially those caused
by atherosclerosis and thrombosis.14 If such an interaction
exists, multifactorial interventions aimed at both lowering BP
and quitting smoking will contribute more to reducing CVD
than expected from past data where their interaction has not
been quantified.
Several epidemiological studies have examined the com-
bined effects of nonoptimal levels of BP and smoking on
cardiovascular events.11,15–23 Some studies, at least partially,
observed a synergistic effect between BP and smoking status
for the risk of CVD,15 CHD,16–18 and stroke (predominately
ischemic),11,16,19,20 whereas other studies did not observe any
such effect.21,22 The majority of these studies were based on
small datasets and crude classifications of BP and smoking
status, and few examined the possible interaction effect
between BP and smoking status for each subtype of CVD. For
hemorrhagic stroke, only 1 case-control study23 examined the
interaction between BP and smoking status; it reported that
interaction was present. Overall, however, the question as to
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whether such an interaction exists, and the nature of this
interaction (synergistic or otherwise), remains unresolved.
The aim of the present study was to examine this issue using
data from the Asia Pacific Cohort Studies Collaboration
(APCSC); an individual participant data overview of prospec-
tive cohort studies conducted in the Asia-Pacific region. The
large size of the dataset provides an ideal opportunity to
explore the joint associations of risk factors with cardiovas-
cular events. In particular, the large numbers of both hemor-
rhagic and ischemic stroke events makes it possible to
measure the risk for each subtype of stroke reliably. Addi-
tionally, APCSC provides a unique opportunity to compare
the association of risk factors with cardiovascular events
between Asian populations and the “Western” populations of
Australia and New Zealand.
Methods
Participating Studies
Details of APCSC are described elsewhere.24,25 Briefly, APCSC is
an overview of preexisting cohort studies in the Asia-Pacific region
which had at least 5000 person-years of follow-up and recorded age,
sex, and BP at baseline, and vital status at the end of the follow-up.
Studies were excluded from APCSC if enrolment was dependent on
having a particular condition or risk factor. Additionally, for analyses
in this report, only persons aged 20 years at study entry with
information on both BP and smoking status were included.
Measurement of Baseline Variables
In most studies, BP was measured at rest in the seated position using
a standard mercury sphygmomanometer. Cigarette smoking habit
was self-reported at study baseline. All studies included here
recorded present smoking status (present smoker or not). Some
studies additionally recorded whether individuals were present,
former, or never smokers, and some recorded cigarettes per day for
smokers. Because most studies, including APCSC, have demon-
strated that the association between systolic blood pressure (SBP)
and cardiovascular events is stronger than that of other BP indices in
most age and gender groups,26,27 we analyzed data on SBP in this
report. Cohorts were classified as Asian if the participants were
recruited from mainland China, Hong Kong, Japan, Korea, Singa-
pore, Taiwan, or Thailand and as ANZ if the participants were from
Australia or New Zealand. This classification largely represented a
split by ethnicity into Asians and Whites.
Outcomes
All studies reported deaths by underlying cause; a subset of studies
also reported nonfatal cardiovascular events. Outcomes were classi-
fied according to the Ninth Revision of the International Classifica-
tion of Diseases (ICD-9). Outcomes in this report, including fatal and
nonfatal events, were CHD (ICD-9: 410 to 414) and stroke (430 to
438), divided into hemorrhagic stroke (intracerebral hemorrhage;
431.0 to 432.9), ischemic stroke (433.0 to 434.9), and other strokes.
Because most studies identified events using record linkage, verifi-
cation of pathological types of stroke was not routinely reported.
All data provided to the Secretariat were checked for complete-
ness and consistency and recoded, when necessary, to maximize
comparability across cohorts. Summary reports were referred back
to principal investigators of each collaborating study for review
and confirmation.
Statistical Methods
Cox proportional hazard regression models adjusted by age and
stratified by study and sex28 were used to estimate hazard ratios
(HRs) and 95% confidence intervals (CIs) for SBP by smoking status
(nonsmokers, including former smokers, and present smokers). To
determine the associations between “usual” level of SBP and the
outcomes of interest, estimates were adjusted for regression dilution
bias.3,29 Repeat measurements of SBP on up to 7 occasions, between
2 and 20 years after the baseline measurement, were obtained from
16 studies for a total of 67 210 participants. These repeat measures
were used to estimate a regression dilution attenuation coefficient for
SBP (1.9), using a linear mixed regression model that accounted for
the heterogeneity of variance between studies and within-subject
correlation.30 Log-linearity of the associations between SBP and
each subtype of cardiovascular event was explored by categorical
analyses in which participants were classified into 4 groups accord-
ing to levels of baseline SBP (130, 130 to 144, 145 to 159, and
160 mm Hg) chosen so as to have approximately equal numbers of
all cardiovascular events across the groups. Corresponding 95% CIs
were calculated by the “floating absolute risk method.”29 HRs and
95% CIs were also derived for a 10 mm Hg increase in the level of
SBP. The interaction effect between SBP and smoking status was
assessed using likelihood ratio tests comparing the models with main
effects only with the models that included the interaction term.29 In
addition to analyses of the overall APCSC, predefined subgroup
analyses were performed by sex, region (Asia and ANZ), and age at
risk (65 and 65 years).24
Further analyses were conducted on subsamples of the total
population which had more detailed information on smoking status.
In one of the subsamples, participants were classified as “present” if
they smoked currently, “never smokers” if they had never smoked,
and “former smokers” if they had smoked but reported having
already quit at study baseline. HRs for a 10-mm Hg increase in the
level of SBP were estimated for each group by this smoking status
and compared using similar methods to the main analyses. Similarly,
dose-response analyses were done on the subset where both the mean
number of cigarettes smoked per day and never smoking were
recorded, comparing never smokers with 20 and 20 cigarettes
per day for present smokers. Groups of 20 and 20 were chosen
to provide an approximately equal partition; 20 cigarettes corre-
sponds to 1 standard pack.
Results
Characteristics of the Study Population
Information on SBP and smoking status was available from
41 cohorts (93% of all studies in APCSC); 32 from Asia
(Table 1). Overall, 563 144 participants were included in the
analysis (82% Asians; 35% female) with a mean age of 47
years. Over one-third (37%) of study participants were
classified as present smokers at baseline, but the prevalence
of smoking differed by sex and region: in Asia, 59% of men
and 5% of women were present smokers versus 20% and
14%, respectively, in ANZ. In Asia, mean age and SBP were
similar between smokers and nonsmokers (45 years versus 45
years and 122 mm Hg versus 121 mm Hg), but in ANZ,
present smokers were both younger and had a lower SBP than
nonsmokers: 48 years versus 54 years and 133 mm Hg versus
138 mm Hg, respectively. These mean values of age and SBP
were weighted, rather than crude, averages across studies.
Information on former smoking status was available from
34 cohorts (24 in Asia). In these, 63 941 (13%) of participants
were former smokers, 261 319 (51%) were never smokers,
and 187 416 (37%) were present smokers. In Asian cohorts,
15% of men and 22% of women who had ever smoked had
quit, compared to 68% and 59%, respectively, in ANZ. Of
these 34 cohorts, 24 also recorded information on the average
number of cigarettes smoked per day. Among the 97 540
present smokers in these cohorts, 44% consumed 20 ciga-
rettes or more per day: in Asia, 44% for men and 21% for
women, versus 52% and 43%, respectively, in ANZ.
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Table 1. Study Population Characteristics by Smoking Status at Baseline
Nonsmokers Current Smokers
Study Name n
Age (years)
mean (SD)
SBP (mm Hg)
mean (SD) Female (%) n
Age (years)
mean (SD)
SBP (mm Hg)
mean (SD) Female (%)
Akabane 1321 55 (8) 125 (19) 77 513 53 (7) 124 (19) 2
Anzhen 5992 54 (13) 129 (24) 69 2386 53 (12) 130 (22) 20
Anzhen02 3287 47 (8) 122 (18) 64 864 46 (8) 122 (17) 1
Beijing aging 1472 70 (9) 143 (25) 62 620 69 (8) 137 (25) 24
Capital Iron Steel Company 1367 45 (8) 125 (19) 0 3775 45 (8) 123 (19) 0
CISCH 1576 44 (7) 117 (17) 69 591 45 (8) 122 (16) 2
Civil service workers 5739 47 (5) 125 (18) 47 3501 47 (5) 126 (18) 10
CVDFACTS 4455 47 (15) 118 (19) 70 1274 48 (16) 119 (18) 4
East Beijing 806 45 (15) 125 (23) 64 322 41 (15) 124 (21) 20
EGAT 1980 43 (5) 121 (17) 38 1514 43 (5) 121 (16) 3
Fangshan 1591 47 (10) 136 (26) 86 1028 48 (10) 135 (25) 36
Guangzhou occupational 87 400 41 (6) 115 (15) 41 79 295 42 (7) 116 (14) 1
Hisayama 918 57 (12) 135 (26) 82 683 55 (10) 135 (26) 22
Hong Kong 2428 79 (7) 150 (25) 63 555 77 (6) 148 (24) 33
Kinmen 1824 63 (10) 138 (23) 64 721 64 (9) 136 (21) 9
KMIC 98 631 44 (7) 121 (14) 54 61 611 45 (7) 125 (14) 0
Konan 857 52 (16) 130 (20) 75 369 51 (16) 130 (18) 9
Miyama 756 61 (10) 134 (22) 73 317 60 (9) 130 (22) 13
Ohasama 1793 60 (11) 127 (17) 78 447 58 (12) 132 (18) 7
Saitama 2588 54 (12) 135 (20) 80 1027 55 (12) 136 (19) 17
Seven cities cohorts 7019 54 (12) 130 (25) 70 3792 54 (12) 129 (23) 26
Shanghai factory workers 5198 47 (7) 124 (21) 51 4149 50 (7) 126 (23) 5
Shibata 1573 57 (11) 130 (21) 82 777 57 (11) 133 (20) 8
Shigaraki town 2657 58 (14) 132 (19) 77 1073 56 (14) 132 (20) 16
Shirakawa 3023 48 (12) 127 (22) 79 1617 48 (12) 126 (21) 8
Singapore heart 1807 40 (13) 124 (22) 61 514 41 (14) 122 (18) 7
Singapore NHS92 2699 39 (12) 119 (19) 62 606 39 (12) 118 (17) 8
Six cohorts 10 465 44 (7) 119 (18) 76 8922 45 (7) 119 (17) 12
Tanno/Soubetsu 1214 51 (7) 134 (20) 78 764 51 (7) 132 (21) 14
Tianjin 4586 56 (13) 139 (28) 64 4749 54 (11) 134 (25) 39
Xi’an 1020 44 (6) 126 (21) 49 675 45 (6) 125 (20) 10
Yunnan 2138 58 (10) 126 (22) 9 4443 55 (9) 123 (21) 0
Total Asia 270 180 45 (10) 121 (18) 53 193 494 45 (9) 122 (17) 4
ALSA 1486 78 (6) 148 (22) 48 124 76 (6) 148 (26) 48
ANHF 7043 44 (14) 126 (18) 53 2234 41 (13) 125 (18) 45
Busselton 5155 45 (17) 138 (25) 59 2634 44 (16) 137 (24) 37
Canberra 728 77 (5) 145 (21) 46 93 76 (5) 147 (22) 39
Fletcher challenge 7899 46 (15) 127 (17) 30 2427 40 (13) 124 (15) 22
Melbourne 36 630 55 (9) 138 (20) 60 4655 53 (8) 135 (19) 47
Newcastle 4567 52 (11) 133 (20) 53 1362 50 (10) 131 (20) 40
Perth 7625 46 (13) 130 (20) 51 2605 43 (13) 129 (19) 40
WAAAAS 10 870 72 (4) 157 (21) 0 1333 71 (4) 157 (22) 0
Total ANZ 82 003 54 (14) 138 (22) 47 17 467 48 (15) 133 (22) 37
Total 352 183 47 (12) 125 (20) 52 210 961 45 (9) 123 (18) 7
SD indicates standard deviation; SBP, systolic blood pressure; ANZ, Australia and New Zealand; ALSA, Australian Longitudinal Study of Aging; ANHF, Australian
National Heart Foundation; CISCH, Capital Iron and Steel Company Hospital; EGAT, Electricity Generating Authority of Thailand; KMIC, Korean Medical Insurance
Corporation; NHS92, National Health Study 1992; WAAAAS, Western Australian AAA Screenees.
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Cardiovascular Outcomes
In total, there were 3 907 543 person-years of follow-up; the
median follow-up was 6.8 years (6.8 years for present
smokers and 6.7 years for nonsmokers) but, for both present
smokers and nonsmokers, it was shorter in Asia (6.8 years
versus 6.0 years) than in ANZ (8.3 years versus 8.2 years;
Table 2). In addition to information on fatal events available
from all cohorts, data on nonfatal CHD events were available
from 14 studies and on nonfatal strokes from 12 studies.
During follow-up, 4344 CHD (1569 in Asia) and 5906 stroke
(4218 in Asia) fatal and nonfatal events were recorded: 76%
(n3282) of CHD events were fatal. Over 80% of CHD
events were myocardial infarction. Of all stroke events, 2001
(1550 in Asia) were classified as ischemic and 1645 (1441 in
Asia) as hemorrhagic: 30% (n608) of ischemic stroke and
73% (n1207) of stroke events were fatal. Diagnosis of
ischemic or hemorrhagic stroke was documented by CT/MRI/
autopsy investigations in 56% of fatal and 65% of nonfatal,
strokes. The percentage of CHD among all CVD (CHD plus
stroke) was similar between smokers and nonsmokers (40%
versus 44%): these percentages in ANZ (61% versus 64%)
were more than double those in Asia (29% versus 25%). The
percentage of hemorrhagic strokes among all strokes was
similar between smokers and nonsmokers (30% versus 26%):
these percentages were higher in Asia (34% versus 34%) than
in ANZ (13% versus 12%).
The Association Between SBP and CHD by
Smoking Status
The HR for CHD increased log-linearly with higher levels of
SBP in both smokers and nonsmokers (Figure 1A). The HRs
(95% CIs) comparing the top to the bottom group of SBP
were 2.27 (2.05 to 2.52) for present smokers and 2.20 (2.05 to
2.36) for nonsmokers. The HR for a 10-mm Hg increase in
SBP level was also similar for present smokers and nonsmok-
ers (Figure 2): 1.29 (1.24 to 1.34) and 1.24 (1.21 to 1.28),
respectively (probability value for interaction0.14). The
coronary HRs for present smokers and nonsmokers were
similar in all sex, age, and region subgroups. Similar results
(not shown) were found for analyses involving fatal events
only.
In the subsample of studies for which information on
former smokers was available, the HRs for CHD associated
with a 10-mm Hg increase in SBP were similar for present
smokers and never smokers. However, the HR was lower in
former smokers than in present or never smokers: 1.28 (1.22
to 1.33) for present smokers, 1.14 (1.09 to 1.20) for former
smokers, and 1.30 (1.25 to 1.35) for never smokers (proba-
bility value for interaction0.0001). In the subsample of
studies with information on cigarette consumption, the HRs
for CHD tended to increase with increasing consumption of
cigarettes: 1.27 (1.21 to 1.32) for never smokers, 1.30 (1.19 to
1.43) for 20 cigarettes per day, and 1.41 (1.28 to 1.54) for
20 cigarettes per day (probability value for interaction0.11).
The Association Between SBP and Ischemic Stroke
by Smoking Status
Similar to CHD, there was no evidence of an interaction
between BP and smoking for risk of ischemic stroke: the HR
for ischemic stroke increased log-linearly with higher levels
of SBP in both present smokers and nonsmokers (Figure 1B).
The HRs (95% CIs) comparing the highest with the lowest
group of SBP were 3.71 (3.22 to 4.27) for present smokers
and 3.82 (3.43 to 4.26) for nonsmokers. The HR for a
10-mm Hg increase in SBP level was similar for present
smokers and nonsmokers in all subgroups (Figure 2). Overall
HRs (95% CIs) were 1.50 (1.43 to 1.57) for present smokers
and 1.47 (1.41 to 1.53) for nonsmokers (probability value for
interaction0.53). Similar results (not shown) were found for
analyses involving fatal events only.
In the subsample with information on former smokers, the
HR for a 10-mm Hg increase in SBP was similar for present
smokers, former smokers, and never smokers: 1.44 (1.36 to
1.52), 1.41 (1.29 to 1.53), and 1.41 (1.34 to 1.49), respec-
tively (probability value for interaction0.86). Among those
participants with information on cigarettes per day there was
marginally nonsignificant evidence of an increasing effect of
SBP with increasing cigarette consumption. The HRs were
1.30 (1.20 to 1.41) for never smokers, 1.47 (1.26 to 1.70) for
20 cigarettes per day, and 1.62 (1.34 to 1.97) for 20
cigarettes per day (probability value for interaction0.06).
The Association Between SBP and Hemorrhagic
Stroke by Smoking Status
The HR for hemorrhagic stroke increased with higher levels
of SBP in both present smokers and nonsmokers (Figure 1C).
There was evidence to support a synergistic effect of smoking
on the association between SBP and hemorrhagic stroke risk:
the HRs (95% CIs) for hemorrhagic stroke comparing the
group with the highest to that with the lowest SBP values
were 9.32 (8.15 to 10.67) for present smokers and 7.05 (6.27
to 7.92) for nonsmokers. The excess risk of hemorrhagic
stroke associated with a 10-mm Hg higher SBP level in-
creased in present smokers compared with nonsmokers by 15
percentage points (ie, 81% versus 66%) (Figure 2): 1.81 (1.73
to 1.90) versus 1.66 (1.59 to 1.73); probability value for
interaction0.003. Subgroup analysis found indications of
this synergistic effect in most subgroups, although it was
statistically significant only for men (P0.01), in Asian study
centers (P0.05), and individuals aged 65 years or over
(P0.008) (Figure 2). Restricting the analysis to fatal hem-
orrhagic events resulted in a similar pattern: HR (95% CI) for
a 10-mm Hg increase in SBP was 1.82 (1.72 to 1.92) for
present smokers and 1.67 (1.59 to 1.75) for nonsmokers
(probability value for interaction0.01).
The HR for a 10-mm Hg increase in SBP was higher in
present smokers than in former smokers and never smokers:
1.87 (1.77 to 1.97) versus 1.55 (1.40 to 1.71) and 1.68 (1.58
to 1.78), respectively (probability value for interac-
tion0.0008). In the subsample with information on ciga-
rettes per day, the HRs increased with higher dose of
smoking: 1.60 (1.47 to 1.75) for never smokers, 1.85 (1.65 to
2.08) for 20 cigarettes per day, and 1.95 (1.72 to 2.22) for
20 cigarettes per day (probability value for interaction0.01).
A sensitivity analysis using only data from participants
(n126 956) in which information on the use of antihyper-
tensive medication status at study baseline was available
indicated that further adjustment for use of antihypertensive
Nakamura et al Smoking and Blood Pressure 1697
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Table 2. Fatal and Nonfatal Cardiovascular Events by Smoking Status
Nonsmokers Current Smokers
Stroke Stroke
Study Name
Median
FUP CHD Isch Hem Others
Median
FUP CHD Isch Hem Others
Akabane 11.0 15 9 5 11 11.0 13 7 6
Anzhen 4.3 50 74 7 4.3 15 32 20 3
Anzhen02 3.0 11 43 3.0 1 3 1 1
Beijing aging 4.8 61 4.8 25
Capital Iron Steel Company 12.5 13 15 20 12.5 70 77 45 9
CISCH 3.3 9 6 3.3 5 3
Civil service workers 6.7 6.7 1 1 1
CVDFACTS 6.1 10 6 5 10 5.8 3 1 3 4
East Beijing 16.0 12 10 8 2 17.4 8 4 3 1
EGAT 11.4 9 8 11.4 24 8
Fangshan 3.6 2 15 6 4 3.6 3 5 2 2
Guangzhou occupational 7.3 60 68 37 7.2 106 99 58
Hisayama 25.1 40 129 29 19 22.6 49 101 39 11
Hong Kong 2.5 73 5 14 41 2.5 13 1 2 10
Kinmen 2.9 6 8 2.9 4 6
KMIC 4.0 107 187 161 150 4.0 171 245 164 147
Konan 6.4 6 2 2 6.4 2 1 1
Miyama 6.6 1 2 2 6.6 1 4 1 1
Ohasama 4.1 2 21 9 4 4.1 5 16 2 2
Saitama 11.0 14 19 9 10 10.0 10 8 6 3
Seven cities cohorts 2.7 51 66 109 6 2.7 33 51 73 2
Shanghai factory workers 14.0 33 114 14.0 53 141
Shibata 20.0 40 46 23 62 20.0 27 31 13 34
Shigaraki town 4.4 2 2 2 1 4.4 1 2 6
Shirakawa 17.5 29 18 20 12 17.5 36 21 11 5
Singapore heart 14.7 40 16 6 37 14.2 26 6 1 9
Singapore NHS92 6.2 22 11 1 19 6.2 11 3 3 8
Six cohorts 9.0 6 33 50 7 8.3 41 71 41 6
Tanno/Soubetsu 16.4 8 7 7 5 16.4 16 3 9 2
Tianjin 6.1 65 58 97 43 6.1 49 64 90 22
Xi’an 19.7 12 8 17 2 19.7 23 7 7
Yunnan 4.5 7 5 42 4.5 11 7 51 1
Total Asia 6.0 738 779 753 690 6.8 831 771 688 537
ALSA 4.7 77 7 8 34 3.3 4 3
ANHF 8.4 55 1 10 8.3 22 1 5
Busselton 26.5 767 153 57 407 26.5 480 85 40 207
Canberra 9.6 106 5 4 23 8.4 14 1 1 4
Fletcher challenge 5.7 202 56 7 101 5.8 71 11 2 17
Melbourne 8.5 262 10 28 43 8.7 61 1 7 11
Newcastle 8.5 78 3 6 15 9.4 59 3 7
Perth 14.4 127 3 7 29 14.4 68 1 3 20
WAAAAS 3.2 285 98 29 86 3.2 37 15 2 11
Total ANZ 8.2 1959 336 146 748 8.3 816 115 58 285
Total 6.7 2697 1115 899 1438 6.8 1647 886 746 822
FUP indicates follow-up (years); CHD, coronary heart disease; Isch, ischemic; Hem, hemorrhagic; ANZ, Australia and New Zealand; ALSA, Australian Longitudinal
Study of Aging; ANHF, Australian National Heart Foundation; CISCH, Capital Iron and Steel Company Hospital; EGAT, Electricity Generating Authority of Thailand; KMIC,
Korean Medical Insurance Corporation; NHS92, National Health Study 1992; WAAAAS, Western Australian AAA Screenees; Blanks indicate that the event was not
reported for that study.
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medication did not attenuate the difference in risk estimates
between present smokers and nonsmokers. The HR (95% CI)
for a 10-mm Hg increase in SBP was 1.42 (1.24 to 1.63) for
present smokers and 1.23 (1.11 to 1.36) for nonsmokers, after
age adjustment (probability value for interaction0.09), and
1.39 (1.21 to 1.60) and 1.20 (1.09 to 1.33), respectively, after
age and use of antihypertensive medication adjustment (prob-
ability value for interaction0.08).
The Association Between SBP and Other Strokes
by Smoking Status
For completeness, Figure 1D shows the categorical analyses
for other strokes. As with ischemic and hemorrhagic strokes,
the HR increased with higher levels of SBP in both present
smokers and nonsmokers. The HRs (95% CIs) comparing the
highest with the lowest group of SBP were 3.17 (2.76 to 3.64)
for present smokers and 3.01 (2.76 to 3.64) for nonsmokers.
The HRs (95% CIs) for a 10-mm Hg increment in SBP level
were 1.40 (1.33 to 1.47) in present smokers and 1.36 (1.31 to
1.41) in nonsmokers (probability value for interaction0.33).
Discussion
The present study demonstrates a log-linear relationship of
SBP with every subtype of CVD, for both smokers and
nonsmokers, with no evidence of a threshold effect down to
usual levels of SBP of 115 mm Hg. For hemorrhagic stroke,
there was evidence that SBP and smoking have a synergistic
effect such that smoking increases the excess risk associated
with a 10-mm Hg increment in SBP by about 15 percentage
points. Our data suggest that this interaction may be specific
to men and older participants, but is unlikely to be specific to
region because of the marginal differences between smokers
and nonsmokers in both Asia and ANZ apparent from Figure
2. By comparison, the excess relative risk associated with
increments in SBP for both CHD and ischemic stroke was
broadly similar for smokers and nonsmokers.
The prevailing cause of CHD and ischemic stroke is
occlusion of the coronary and cerebral arteries due to athero-
sclerosis and thrombosis.14 Some previous reports suggest
that nonoptimal levels of BP combined with smoking may
promote atherothrombogenesis.12,13 Kiyohara and colleagues16
observed an interaction effect between BP and smoking status
for CHD in women but not in men, and 1 study17 observed
such an effect in women. Meanwhile, 1 study18 observed such
an effect in men. In a case-control study, Ohgren and
colleagues19 reported an interaction effect between BP and
smoking status for all strokes (78% of which were ischemic).
Two Japanese studies11,16 observed such a potentiation for
ischemic stroke among men (but not women16), as did the
British Regional Heart Study,20 in which the majority of
strokes would be expected to be ischemic in origin. By
contrast, 2 studies21,22 in populations where ischemic stroke
predominates did not observe such a potentiation for all
strokes. These null findings are consistent with our results
based on the simple assessment of present smoking status (ie,
present/nonsmokers, and present/former/never smokers), sug-
gesting that smoking does not exacerbate the association
between SBP and the risk of CHD and ischemic stroke.
Furthermore, as most of the previous studies used a relatively
crude classification of smoking and hypertensive status,
previous positive findings of an interaction may have been
attributable to chance alone. There was however some sug-
Figure 1. Associations between usual systolic
blood pressure (SBP) and overall events by
smoking status for: (A) coronary heart disease,
(B) ischemic stroke, (C) hemorrhagic stroke,
and (D) other strokes. The hazard ratio (95%
confidence interval) for the lowest group of
SBP is fixed at 1.0, separately for present
smokers and nonsmokers. Analyses are
adjusted by age and stratified by study and
sex. The dashed (right) and continuous (left)
lines represent present smokers and nonsmok-
ers, respectively. (Probability values for log-
linearity 0.0001 for all.)
Nakamura et al Smoking and Blood Pressure 1699
 at CONS KESLI on October 27, 2014http://stroke.ahajournals.org/Downloaded from 
gestion of an interaction for CHD and ischemic stroke when
restricting the present analysis to those studies with informa-
tion on cigarette consumption, in agreement with an earlier
study11 which reported that the risk of ischemic stroke
increased more strongly with higher dose of smoking among
individuals with hypertension compared with those without.
By contrast, another study21 reported that the smoking dose-
related risk for all strokes was similar for both those with and
without hypertension.
Unlike CHD and ischemic stroke, the prevailing cause of
hemorrhagic stroke is rupture resulting from fragility (includ-
ing microaneurysms) of the intracerebral penetrating arteries
caused by nonoptimal levels of BP or amyloid angiopa-
thy.31,32 This accounts for the stronger association between
BP and hemorrhagic stroke risk compared with CHD, al-
though the risk related to increased levels of BP is similar for
ischemic and hemorrhagic stroke.4,5 By contrast, the excess
risk attributable to smoking for hemorrhagic stroke is less
than it is for either CHD or ischemic stroke.9–11As regards a
pathophysiological mechanism behind the interaction for
hemorrhagic stroke observed in the present study, we can
only speculate that smoking may promote the weakening of
the intracranial blood vessels caused by high levels of BP or
amyloid angiopathy. Only Thrift and colleagues23 have ex-
amined the interaction between BP and smoking status for
hemorrhagic stroke events. In this case-control study, a
significant synergistic interaction was observed only in men,
which is consistent with our findings. The sex-specific effect
that we observed may have been a chance finding as a
consequence of the few events among the smaller population
of female smokers (n14 031), compared with male smokers
(n196 930). The regional specificity may result from the
difficulty in observing hemorrhagic stroke events due to a
much smaller number participants and a lower event rate of
hemorrhagic stroke in ANZ (204 events per 99 470 ANZ
participants) compared with Asia (1411 events per 463 674
Figure 2. Hazard ratios (HRs) associated with a 10-mm Hg increase in usual systolic blood pressure for coronary heart disease (CHD),
ischemic stroke, and hemorrhagic (Hem) stroke, in present smokers and nonsmokers, by sex, region, age, and overall. Analyses are
adjusted by age and stratified by study and sex. The horizontal lines (or widths of diamonds for overall results) show 95% confidence
intervals (CIs). The probability values shown are for the test of interaction between systolic blood pressure and smoking status. The
dashed (lower) and continuous (upper) lines represent present smokers and nonsmokers, respectively.
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Asian participants). However, neither of these explanations
would explain the age-specific significant effect, wherein the
interaction only occurred among those aged 65 years or over:
883 events for 65 years and 762 events for 65 years.
The present study has some limitations. First, some cohorts
in APCSC do not have information on other risk factors for
CVD at baseline, restricting our ability to adjust for important
covariates which may explain the observed interaction effects
between BP and smoking. Serum total cholesterol, which is
positively associated with CHD and ischemic stroke events,
and inversely with hemorrhagic stroke events,33 was available
on 353 158 individuals; data on other potentially useful
covariates was less common. However, adjustment for total
cholesterol had negligible impact on any of the reported
results (not shown). Second, we had limited data on daily
dose of smoking and little information on how smoking status
changed during follow-up, which did not allow any reliable
analyses of follow-up smoking status comparable to our
treatment of SBP. Third, the main analysis was not adjusted
for antihypertensive medication status because of a lack of
this information for more than 70% of participants, although
the sensitivity analysis suggests that it may have little
material impact on the results. Finally, there was lack of
standardization of methods and procedures among the partic-
ipating studies in APCSC, because the participating studies
were originally independent of each other. For instance, only
56% of fatal and 65% of nonfatal strokes were objectively
(using CT/MRI or autopsy findings) classified as ischemic or
hemorrhagic in origin. The Hisayama study in Japan,34 1 of
the APCSC participating studies, investigated the accuracy of
diagnosis of each subtype of CVD using autopsies in the
1960s, 1970s, and 1980s. The accuracy of diagnosis was
similar for ischemic and hemorrhagic stroke (confirmation
rate 60% to 70%), which was better than the accuracy for
CHD (46%).34 Therefore, misclassification of stroke subtype
may have introduced bias the extent of which would have
varied across the studies.
In conclusion, we have shown that a combination of
present smoking and nonoptimal levels of BP appears to have
a synergistic impact on the risk of hemorrhagic stroke, at least
among men and in the elderly, although the underlying
pathophysiological mechanism is unclear, and we cannot
exclude that similar synergism may occur among younger
people and women. Furthermore, we cannot affirm the
absence of interaction between BP and smoking for CHD and
ischemic stroke. Further studies allowing for better verifica-
tion of pathological types of stroke, better assessment of
smoking status and other variables, and using a larger and
more standardized dataset, are warranted to determine
whether the interaction between BP and smoking really exists
for each subtype of CVD, what mechanism explains the
interaction, and how specific it is to demographic groups.
Although quitting smoking and lowering BP are both crucial
for prevention of CVD, combining the two could be expected
to have extra beneficial effect on preventing hemorrhagic
stroke. Thus, smoking cessation initiatives should be targeted
more rigorously for hypertensive patients to prevent hemor-
rhagic stroke.
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